GlaxoSmithKline CEO Andrew Witty attributes the company’s success to sticking to the tried-and-true business model of investing in research and development and not transitioning to an acquisition model.
Witty told CNBC’s “Closing Bell” on Monday that the key is to be patient and to see the value of investing in innovation.
{iframe}http://www.cnbc.com/2016/05/02/gsk-ceo-big-pharma-should-keep-investing-in-rd.html{/iframe}